EVH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Evolent Health's share price is $8.55. Evolent Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $22.28. Hence, Evolent Health's PS Ratio for today is 0.38.
Good Sign:
Evolent Health Inc stock PS Ratio (=0.39) is close to 10-year low of 0.39
The historical rank and industry rank for Evolent Health's PS Ratio or its related term are showing as below:
During the past 12 years, Evolent Health's highest PS Ratio was 77.57. The lowest was 0.39. And the median was 2.16.
Evolent Health's Revenue per Sharefor the three months ended in Dec. 2024 was $5.62. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $22.28.
During the past 12 months, the average Revenue per Share Growth Rate of Evolent Health was 26.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 28.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 21.00% per year.
During the past 12 years, Evolent Health's highest 3-Year average Revenue per Share Growth Rate was 103.30% per year. The lowest was 9.20% per year. And the median was 18.75% per year.
The historical data trend for Evolent Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
1.47 | 2.62 | 1.95 | 1.87 | 0.51 |
Evolent Health Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.87 | 1.70 | 0.92 | 1.31 | 0.51 |
For the Health Information Services subindustry, Evolent Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Evolent Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Evolent Health's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 8.55 | / | 22.277 | |
= | 0.38 |
Evolent Health's Share Price of today is $8.55.
Evolent Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
Evolent Health (NYSE:EVH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Evolent Health's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Joseph Mccarthy | officer: PRESIDENT | 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
John Paul Johnson | officer: Chief Financial Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Emily Ann Rafferty | officer: Chief Operating Officer | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Seth Blackley | officer: President | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Jonathan Weinberg | officer: General Counsel | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Toyin Ajayi | director | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Cheryl Scott | director | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Mary Bridget Duffy | director | C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126 |
Diane Holder | director | 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Richard M Jelinek | director | 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035 |
Frank J Williams | director, officer: Chief Executive Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Steve Tutewohl | officer: Chief Operating Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Tunde Sotunde | director | 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203 |
Kim Keck | director | 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603 |
Craig A. Barbarosh | director | 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305 |
From GuruFocus
By GuruFocus News • 11-08-2024
By PRNewswire • 10-22-2024
By GuruFocus News • 10-17-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 01-28-2025
By PRNewswire • 12-18-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 11-07-2024
By GuruFocus News • 12-03-2024
By GuruFocus News • 12-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.